Phase I Study of Inhaled Vidaza® in Patients With Advanced NSCLC

Trial Profile

Phase I Study of Inhaled Vidaza® in Patients With Advanced NSCLC

Recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Mar 2017

At a glance

  • Drugs Azacitidine (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 24 Mar 2015 Protocol has been amended to change in incl/excl criteria, treatment arms, primary endpoint and patient number.
    • 24 Mar 2015 Planned primary completion date changed from 1 Nov 2015 to 1 Nov 2016 as reported by ClinicalTrials.gov.
    • 04 Jun 2014 Trial status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top